SEHK:9966
SEHK:9966Biotechs

A Look At Alphamab Oncology (SEHK:9966) Valuation After KN035 Regulatory Milestone In Biliary Tract Cancer

The latest development at Alphamab Oncology (SEHK:9966) involves China’s regulator formally accepting its new drug application for KN035, in combination with Gemcitabine and Oxaliplatin, for first-line treatment of unresectable or metastatic biliary tract cancer. See our latest analysis for Alphamab Oncology. After the NMPA accepted the KN035 filing, Alphamab Oncology’s HK$10.28 share price sits alongside a 1-year total shareholder return of 216.31%, while the 90-day share price return of a...
SEHK:2382
SEHK:2382Electronic

Sunny Optical’s New Share Buyback Mandate Could Be A Game Changer For Sunny Optical (SEHK:2382)

On January 8, 2026, Sunny Optical Technology (Group) Company Limited (SEHK:2382) began repurchasing its own shares under a shareholder-approved mandate allowing buybacks of up to 109,480,480 shares, or 10% of its issued capital, funded from legally available resources in line with Cayman Islands law and Hong Kong Listing Rules. The program, which aims to lift net asset value and earnings per share before the authority expires at the next Annual General Meeting or once fully used, signals...